Background: With the increasing availability biosimilars, the role of pharmacists as drug information specialists has expanded to include promoting biosimilar acceptance among prescribers.
Objectives: Our study aimed to determine Malaysian hospital pharmacists' perspectives on biosimilars and to identify factors influencing the successful promotion of biosimilars to prescribers.
Methods: This was a cross-sectional, web-based survey of hospital pharmacists across Malaysia. Multivariate logistic regression analysis was used to identify factors associated with pharmacists successfully promoting biosimilar use.
Results: Of the 913 responses, over 60% of pharmacists believed that patients may safely be switched from the originator product to a biosimilar and would have the same clinical outcome. Many lacked training in biosimilars (62.8%); yet most (80.6%) perceived pharmacists to play a critical role in promoting biosimilar prescribing. Multivariate logistic regression analysis showed that the strongest factor associated with pharmacists' successful promotion of biosimilars to prescribers was having confidence (odds ratio [OR], 3.33; 95% confidence interval [CI] 2.10-5.26). Respondents who had prior experience handling biosimilars were more likely to be successful in promoting biosimilar use than those without (OR, 1.76; 95% CI 1.16-2.66). The pharmacists' top perceived barrier to promote biosimilars in clinical practice was efficacy concerns.
Conclusion: Although Malaysian pharmacists are in favour of biosimilars, they lack training to promote biosimilar use. Among the factors associated with successful promotion of biosimilars to prescribers are pharmacist confidence, their previous experience handling biosimilars, and prior biosimilar training.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791626 | PMC |
| http://dx.doi.org/10.1007/s40259-022-00571-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The impact of financial incentives promoting biosimilar products in oncology: A quasi-experimental study using administrative data.
PLoS One
November 2024
Department of Healthcare Economics and Quality Management, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Background: Biosimilars have the potential to save a significant amount of money in cancer treatment costs. However, barriers exist in the adoption of biosimilar products. Japan introduced a new health policy in 2022 to promote the use of biosimilars in oncology by offering financial incentives to eligible hospitals.
View Article and Find Full Text PDFAnalysis of the situation of pharmaceutical care for patients with immune-mediated inflammatory diseases before and after the COVID-19 pandemic.
Farm Hosp
November 2024
Servicio de Farmacia - Hospital Universitari i Politècnic La Fe, Valencia, Spain; Grupo de Trabajo de Enfermedades Inflamatorias Inmunomediadas de la Sociedad Española de Farmacia Hospitalaria (GTEII SEFH), Madrid, Spain. Electronic address:
Objective: To describe, analyse, and compare the situation of pharmaceutical care consultations for outpatients with immune-mediated inflammatory diseases of the Pharmacy Services of Spain at 2 different times.
Method: Longitudinal, multicentre, and unidisciplinary descriptive observational study, carried out by the Immune-mediated Inflammatory Diseases Working Group of the Spanish Society of Hospital Pharmacy through a virtual survey in 2019 and 2021. Variables were collected regarding coordination, resources, biosimilars, unmet needs, and telepharmacy.
Expert Consensus Recommendations on a Biosimilars Value Framework for the Gulf Cooperation Council Countries.
Ther Innov Regul Sci
October 2024
Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Objective: This paper aims to develop a biosimilar value framework with local stakeholders in Gulf Cooperation Council (GCC) countries.
Methods: A convenience sample of ten key opinion leaders from the United Arab Emirates, Kingdom of Saudi Arabia, Kuwait, Oman and Qatar participated in an expert panel meeting in November 2022 that examined factors positively influencing biosimilar adoption in these countries. The discussion was structured around a conceptual biosimilar value framework and an overview of biosimilar policies as derived from a targeted review of the peer-reviewed and grey literature.
Public deliberation to assess patient views on biosimilar medication switching for the treatment of inflammatory bowel disease.
BMC Health Serv Res
October 2024
Health Services Research and Development Center of Clinical Management Research, VHA Ann Arbor, Ann Arbor, MI, USA.
Background: Biosimilars are highly similar, but not identical, versions of originator biologic medications. Switching patients to biosimilars presents an opportunity to mitigate rising drug costs and expand patient access to important biologic therapies. However, decreased patient acceptance and adherence to biosimilar medications have been reported, which can lead to loss of treatment response, adverse reactions, and inefficient resource utilization.
View Article and Find Full Text PDFRecommendations for Interchangeability in a Growing Biosimilar Market in Latin America.
Adv Ther
December 2024
Edumed-Health Research and Education, Rua Bispo Dom José 2495, Batel Curitiba, Paraná, Brazil.
Article Synopsis
- - Biosimilars can greatly improve access to biologic treatments in Latin America, but their adoption is hindered by misunderstandings, regulatory issues, and insufficient monitoring of their use.
- - A panel of experts recommended enhancing regulations, improving transparency, establishing solid monitoring systems, and fostering collaboration among various stakeholders to better educate about the benefits of biosimilars.
- - To successfully integrate biosimilars and their interchangeability, Latin American countries need to close knowledge gaps and biases among healthcare providers and patients, which can be achieved through effective communication and real-world evidence.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!